Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00265265 · ClinicalTrials.gov registry record · Phase 1
Assessment of Potential Interactions Between Intravenous Cocaine and Atomoxetine - 1
A Phase 1 study, sponsored by National Institute on Drug Abuse (NIDA).
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT00265265 is a Phase 1 study that has completed, run by National Institute on Drug Abuse (NIDA). The registered enrollment target is 16 participants.
The verdict
NCT00265265, a Phase 1 study, has completed, sponsored by National Institute on Drug Abuse (NIDA).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
The purpose of this study is to assess potential interactions between intravenous (i.v.) cocaine and atomoxetine (Strattera) administered orally in four escalating doses.
Interventions
- DRUG Atomoxetine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2005-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00265265
The ClinicalTrials.gov registry entry for NCT00265265 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute on Drug Abuse (NIDA), which has 335 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Atomoxetine is the first listed.
NCT00265265 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00265265 about?
NCT00265265 is a clinical study titled "Assessment of Potential Interactions Between Intravenous Cocaine and Atomoxetine - 1". The purpose of this study is to assess potential interactions between intravenous (i.v.) cocaine and atomoxetine (Strattera) administered orally in four escalating doses.
What is the current status of trial NCT00265265?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2005-08.
What interventions are being tested in trial NCT00265265?
The interventions under investigation include: Atomoxetine (DRUG).
Who is sponsoring clinical trial NCT00265265?
This trial is sponsored by National Institute on Drug Abuse (NIDA), which has 335 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.